1. GPCR/G Protein
  2. Glucagon Receptor

Glucagon Receptor

Glucagon receptor is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Glucagon Receptor Related Products (62):

Cat. No. Product Name Effect Purity
  • HY-13443
    Exendin-4 Agonist 99.98%
    Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P0014
    Liraglutide Agonist 99.45%
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
  • HY-P0082
    Glucagon 99.81%
    Glucagon (Porcine glucagon) is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis[1]. Glucagon activates HNF4α and increases HNF4α phosphorylation[2][3].
  • HY-P0264
    Avexitide Antagonist 99.70%
    Avexitide (Exendin (9-39)) is a specific and competitive GLP-1 receptor antagonist.
  • HY-19904
    Adomeglivant Antagonist 99.84%
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus[1][2][3].
  • HY-P3101A
    GLP-1(28-36)amide TFA
    GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects[1].
  • HY-P3102
    GLP-1(32-36)amide
    GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice[1][2].
  • HY-P3102A
    GLP-1(32-36)amide TFA
    GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice[1][2].
  • HY-114118A
    Semaglutide TFA Agonist 98.24%
    Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
  • HY-P0055
    GLP-1(7-37) 99.87%
    GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
  • HY-13443A
    Exendin-4 acetate Agonist 99.44%
    Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P0054
    GLP-1(7-36), amide acetate 98.62%
    GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
  • HY-50663
    MK 0893 Antagonist 99.33%
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
  • HY-P1731B
    Tirzepatide hydrochloride Agonist 98.85%
    Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes[1].
  • HY-114118
    Semaglutide Agonist 99.84%
    Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
  • HY-103546
    BETP Agonist 99.28%
    BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.
  • HY-125824
    PF-06882961 Agonist 99.03%
    PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R)[1][2].
  • HY-50675
    GRA Ex-25 Inhibitor 99.70%
    GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.
  • HY-112185
    GLP-1 receptor agonist 1 Agonist 99.42%
    GLP-1 receptor agonist 1 is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67[1].
  • HY-12525
    LGD-6972 Antagonist >98.0%
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research[1].